Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.36 USD
+0.02 (0.85%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $2.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ESPR 2.36 +0.02(0.85%)
Will ESPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
Other News for ESPR
Optimizing Cash Flow and Market Potential: A Buy Rating for Esperion
What You Missed On Wall Street This Morning
Esperion’s Strategic Financial Moves and Regulatory Successes Prompt a Buy Rating
Fly Intel: Pre-market Movers
Esperion Secures Funding and Clears Debt through Royalty Deal